DSM Capital Partners LLC Purchases 1,027,633 Shares of DexCom, Inc. $DXCM

DSM Capital Partners LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 252.1% in the 2nd quarter, Holdings Channel reports. The firm owned 1,435,296 shares of the medical device company’s stock after purchasing an additional 1,027,633 shares during the quarter. DexCom accounts for 1.9% of DSM Capital Partners LLC’s investment portfolio, making the stock its 17th largest holding. DSM Capital Partners LLC’s holdings in DexCom were worth $125,287,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Golden State Wealth Management LLC raised its position in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in DexCom during the 1st quarter worth $27,000. Anderson Financial Strategies LLC bought a new position in DexCom during the 1st quarter worth $37,000. Alpine Bank Wealth Management bought a new position in DexCom during the 1st quarter worth $40,000. Finally, Private Trust Co. NA raised its position in DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after purchasing an additional 335 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on DXCM. Mizuho increased their price target on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Piper Sandler lifted their price objective on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Oppenheimer lowered DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Finally, Truist Financial began coverage on DexCom in a research report on Monday, June 16th. They issued a “buy” rating and a $102.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $97.42.

DexCom Stock Performance

Shares of DXCM opened at $65.12 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The stock has a 50-day moving average of $74.42 and a 200-day moving average of $77.62. The company has a market cap of $25.54 billion, a PE ratio of 45.22, a P/E/G ratio of 1.43 and a beta of 1.47. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period last year, the business posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the sale, the director directly owned 51,121 shares in the company, valued at $4,143,868.26. This trade represents a 5.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.